WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

Company is among the first in China’s drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company’s robust quality management system SHANGHAI, April 15, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO […]